MX2022008490A - Metodos de tratamiento de la esplenomegalia. - Google Patents

Metodos de tratamiento de la esplenomegalia.

Info

Publication number
MX2022008490A
MX2022008490A MX2022008490A MX2022008490A MX2022008490A MX 2022008490 A MX2022008490 A MX 2022008490A MX 2022008490 A MX2022008490 A MX 2022008490A MX 2022008490 A MX2022008490 A MX 2022008490A MX 2022008490 A MX2022008490 A MX 2022008490A
Authority
MX
Mexico
Prior art keywords
methods
splenomegaly
treating
treating splenomegaly
therapeutic methods
Prior art date
Application number
MX2022008490A
Other languages
English (en)
Inventor
Wayne Philip Rothbaum
Original Assignee
Telios Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telios Pharma Inc filed Critical Telios Pharma Inc
Publication of MX2022008490A publication Critical patent/MX2022008490A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Processing Of Solid Wastes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen métodos terapéuticos y composiciones farmacéuticas para tratar la esplenomegalia en un sujeto humano. En ciertas realizaciones, la invención incluye métodos terapéuticos para tratar la esplenomegalia usando un inhibidor de BTK.
MX2022008490A 2020-01-08 2021-01-08 Metodos de tratamiento de la esplenomegalia. MX2022008490A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062958632P 2020-01-08 2020-01-08
PCT/US2021/012696 WO2021142257A1 (en) 2020-01-08 2021-01-08 Methods of treating splenomegaly

Publications (1)

Publication Number Publication Date
MX2022008490A true MX2022008490A (es) 2022-10-13

Family

ID=76788747

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008490A MX2022008490A (es) 2020-01-08 2021-01-08 Metodos de tratamiento de la esplenomegalia.

Country Status (14)

Country Link
EP (2) EP4000624A1 (es)
JP (1) JP2023509968A (es)
KR (1) KR20220130151A (es)
CN (1) CN114423457A (es)
AU (1) AU2021205484A1 (es)
BR (1) BR112022013646A2 (es)
CA (1) CA3164063A1 (es)
CO (1) CO2022010592A2 (es)
CR (1) CR20220374A (es)
IL (1) IL294582A (es)
JO (1) JOP20220168A1 (es)
MA (1) MA57226B1 (es)
MX (1) MX2022008490A (es)
WO (1) WO2021142257A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240024314A1 (en) 2020-01-08 2024-01-25 Telios Pharma, Inc. Methods of Treating Splenomegaly
KR20220130151A (ko) * 2020-01-08 2022-09-26 텔리오스 파마, 인크. 비장비대의 치료 방법
WO2023071973A1 (en) * 2021-10-26 2023-05-04 Shenzhen Targetrx, Inc. Fused bicyclic compound for inhibiting activity of tyrosine kinase
WO2024041614A1 (en) * 2022-08-25 2024-02-29 Beigene Switzerland Gmbh Solid forms comprising (s) -7- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahydropyrazolo [1, 5-a] pyrimidine-3-carboxamide, and oxalic acid, compositions and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
DK3179991T3 (da) * 2014-08-11 2021-12-06 Acerta Pharma Bv Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor
US9708348B2 (en) * 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
WO2019243223A1 (en) * 2018-06-19 2019-12-26 Merck Patent Gmbh Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
KR20220130151A (ko) * 2020-01-08 2022-09-26 텔리오스 파마, 인크. 비장비대의 치료 방법

Also Published As

Publication number Publication date
CA3164063A1 (en) 2021-07-15
EP3980069A4 (en) 2022-08-17
MA57226A1 (fr) 2023-02-28
AU2021205484A1 (en) 2022-08-18
CR20220374A (es) 2023-01-25
JOP20220168A1 (ar) 2023-01-30
IL294582A (en) 2022-09-01
CN114423457A (zh) 2022-04-29
MA57226B1 (fr) 2023-06-28
JP2023509968A (ja) 2023-03-10
WO2021142257A1 (en) 2021-07-15
KR20220130151A (ko) 2022-09-26
BR112022013646A2 (pt) 2022-10-04
EP4000624A1 (en) 2022-05-25
EP3980069A1 (en) 2022-04-13
CO2022010592A2 (es) 2022-10-31

Similar Documents

Publication Publication Date Title
JOP20220168A1 (ar) طرق علاج الطحال
MX2022005994A (es) Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2022004983A (es) Composiciones de profarmaco y metodos de tratamiento.
MX2021011110A (es) Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana.
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
MX2020011817A (es) Metodos para tratar el linfoma.
MX2021009051A (es) Tratamiento de lesiones cutaneas y prurito en pacientes con prurigo nodular.
PH12020551820A1 (en) Methods of treating cancer
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2021005992A (es) Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
PH12017500392A1 (en) Medical treatments based on anamorelin
CR20220280A (es) Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2
JOP20210245A1 (ar) طرق لعلاج الداء النشواني من النوع خفيف السلسلة
MX2023006419A (es) Compuestos polipéptidos modificados con lactama.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
CR20210514A (es) USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183)
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
MX2021009413A (es) Materiales y métodos para tratar una enfermedad neurodegenerativa.
MX2021004396A (es) Metodos y composiciones para el tratamiento de la mucositis oral.
MX2022005358A (es) Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso.
MX2022007516A (es) Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos.
MX2020012407A (es) Metodos de tratamiento del trastorno de deficit de atencion e hiperactividad.